Vanguard Capital Management’s Faeth Therapeutics FTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$28.3M Buy
951,721
+941,606
+9,309% +$29.3M ﹤0.01% 2210
2026
Q2
$253K Buy
10,115
+2,365
+31% +$54.7K ﹤0.01% 3801
2026
Q1
$244K Buy
+7,750
New +$155K ﹤0.01% 3773

Other funds holding FTH

Vanguard Capital Management's FTH Position: Q3 2026 in Review

Vanguard Capital Management increased its Faeth Therapeutics (FTH) stake by 9,309% in Q3 2026, buying an estimated $29.3M and bringing the position to 951,721 shares worth $28.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2210.

Vanguard Capital Management first reported a position in FTH in Q1 2026 and has held it in 3 quarters since. 78 funds tracked by Wall St. Rank hold FTH as of Q3 2026.

  • Vanguard Capital Management held 951,721 shares of Faeth Therapeutics worth $28.3M as of Q3 2026.
  • Vanguard Capital Management bought 941,606 Faeth Therapeutics shares in Q3 2026, an estimated $29.3M.
  • Faeth Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2210 holding.
  • Vanguard Capital Management first reported a position in Faeth Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 78 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.